The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.

@article{Mikamo2018TheEO,
  title={The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.},
  author={Hiroshiege Mikamo and Norihiro Aoyama and Miyuki Sawata and Go Fujimoto and Mary Beth Dorr and Tomoko Yoshinari},
  journal={Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy},
  year={2018},
  volume={24 2},
  pages={
          123-129
        }
}
Recurrent Clostridium difficile infection is considered as a significant health care burden. The global study (MODIFY II) of antibody treatment (bezlotoxumab) for the prevention of recurrent C. difficile infection includes Japanese patients (95 subjects); The aim of this subgroup analysis is to report the data obtained from Japanese patients. Patients with C. difficile infection receiving standard of care antibiotic treatment and a single infusion of bezlotoxumab 10 mg/kg, actoxumab 10 mg/kg… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
The standard of care antibiotic for C. difficile infection was metronidazole for 57 subjects and vancomycin for 36 subjects .
The standard of care antibiotic for C. difficile infection was metronidazole for 57 subjects and vancomycin for 36 subjects .
All Topics